Group 1 - The pharmaceutical manufacturing industry in Qing'an County is focusing on technological innovation as a core driver for development, aiming for breakthroughs in formulation, intelligent upgrades, and cross-industry integration [1] - Heilongjiang Aolida Naide Pharmaceutical has invested nearly 50 million yuan in consistency evaluation for generic drugs, resulting in five products approved for market, including a unique product with a market share of 70% to 80% [1] - The company is also expanding its product matrix with new approvals expected this year, including oral solutions and small-volume injectables [1] Group 2 - Heilongjiang Zhonggui Pharmaceutical has established a high-level innovation platform recognized by the provincial government, with an annual investment of about 20 million yuan in technology innovation and new product development [2] - The company has received awards for its industrialization of oral solutions and has secured funding for major technological achievements, promoting a cycle of research, transformation, and industrialization [2] - Heilongjiang Ruige Pharmaceutical is undergoing a digital and intelligent transformation in traditional Chinese medicine manufacturing, enhancing production stability and increasing extraction rates by at least 10% [2] Group 3 - Heilongjiang Kelong Pharmaceutical is diversifying into the health beverage market, leveraging its pharmaceutical-grade production environment to create products from local resources, aligning with consumer trends and seeking new growth opportunities [3] - By 2026, Qing'an County aims to leverage technological innovation to drive high-quality development in key industries, contributing to the revitalization of Northeast China and the establishment of a modernized Heilongjiang [3]

Core Viewpoint - The company has received approval for a new product, which is expected to enhance its product line in the respiratory system and complement its existing innovative drugs [2]. Group 1: Company Performance - As of December 24, 2025, the stock price of Zhongsheng Pharmaceutical (002317) closed at 19.46 yuan, down 0.05%, with a turnover rate of 7.28%, trading volume of 554,100 hands, and a transaction amount of 1.08 billion yuan [1]. - On the same day, the net outflow of main funds was 2.8084 million yuan, while the net inflow of speculative funds was 21.1941 million yuan, and the net outflow of retail funds was 18.3858 million yuan [1][3]. Group 2: Product Development - The company has obtained the drug registration certificate for Ambroxol Hydrochloride Oral Solution, with approved specifications of 10ml:30mg and 100ml:0.3g, classified as a Category 4 chemical drug, equivalent to passing the consistency evaluation for generic drugs [2]. - The Ambroxol Hydrochloride Oral Solution is indicated for the treatment of viscous phlegm and difficulty in expectoration caused by acute and chronic bronchitis, and it is listed as a Class B drug under medical insurance [2]. - The projected sales for this product in Chinese public hospitals and urban retail pharmacies are 710.84 million yuan for 2022, 817.66 million yuan for 2023, and 849.53 million yuan for 2024 [2].

Core Viewpoint - Guangdong Zhongsheng Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for the registration of its oral solution of Ambroxol Hydrochloride, which is indicated for the treatment of bronchitis-related symptoms [2] Group 1 - The approved product, Ambroxol Hydrochloride oral solution, is suitable for both acute and chronic bronchitis, specifically addressing issues related to thick phlegm and difficulty in expectoration [2] - The announcement highlights that there are clear clinical guidelines recommending the use of this medication for the specified conditions [2]

Core Viewpoint - The company has received the drug registration certificate for Ambroxol Hydrochloride Oral Solution, which is expected to enhance its market competitiveness and positively impact future performance [1][4]. Group 1: Drug Registration Information - The drug name is Ambroxol Hydrochloride Oral Solution, available in two specifications: 10ml: 30mg and 100ml: 0.3g [1]. - It is classified as a Class 4 chemical drug and has been approved for domestic production [1]. - The approval numbers are 2025S03794 and 2025S03795, with the drug approval document numbers being 国药准字H20256278 and 国药准字H20256279 [1]. Group 2: Product Overview - Ambroxol Hydrochloride is a mucolytic agent that helps reduce mucus viscosity and facilitates expectoration, making it suitable for treating acute and chronic bronchitis [2]. - The product is classified as a Category B drug under medical insurance and has shown sales growth in public hospitals and urban pharmacies in China, with total sales of RMB 71.084 million in 2022, RMB 81.766 million in 2023, and RMB 84.953 million projected for 2024 [2]. - This approval marks another product that has passed the consistency evaluation for generic drugs, complementing the company's existing respiratory medications [2]. Group 3: Impact on the Company - The approval of Ambroxol Hydrochloride Oral Solution is expected to enhance the company's market position and contribute positively to future performance [4]. - However, the sales performance may be influenced by national policies and market conditions, indicating a level of uncertainty [4].

Core Viewpoint - The company, Zhongsheng Pharmaceutical, has received approval from the National Medical Products Administration for the registration of its oral solution of Ambroxol Hydrochloride, which is indicated for the treatment of bronchitis-related symptoms [1] Group 1 - The oral solution of Ambroxol Hydrochloride is suitable for both acute and chronic bronchitis, specifically addressing issues related to thick phlegm and difficulty in expectoration [1] - The product has clear diagnostic and treatment guidelines recommended for its use [1]

Core Viewpoint - Zhongsheng Pharmaceutical (002317.SZ) has received the drug registration certificate for Ambroxol Hydrochloride Oral Solution from the National Medical Products Administration, indicating a significant regulatory approval for a new product in its portfolio [1] Group 1: Product Information - Ambroxol Hydrochloride is a mucolytic agent that increases the secretion of serous glands in the respiratory mucosa and reduces the secretion of mucus glands, thereby lowering the viscosity of phlegm [1] - The product promotes the secretion of pulmonary surfactant and enhances bronchial ciliary movement, making it easier to expel phlegm [1] - The oral solution is indicated for the treatment of viscous phlegm and difficulty in expectoration caused by acute and chronic bronchitis, with clear diagnostic and therapeutic guidelines recommended [1]

Core Viewpoint - The approval of the oral solution of Ambroxol Hydrochloride by the National Medical Products Administration signifies a significant milestone for the company, enhancing its product line in the respiratory treatment sector [1] Group 1: Product Approval - The company has received the drug registration certificate for Ambroxol Hydrochloride oral solution from the National Medical Products Administration [1] - This product is classified as a Category B drug under the medical insurance system in China [1] Group 2: Market Potential - The projected sales for Ambroxol Hydrochloride oral solution in public hospitals and urban pharmacies in China are estimated to be 711 million yuan in 2022, 818 million yuan in 2023, and 850 million yuan in 2024 [1] - The approval indicates that the product has passed the consistency evaluation for chemical generic drugs, which is expected to further enrich the company's offerings in the respiratory treatment market [1]

Core Viewpoint - Changfeng Pharmaceutical Co., Ltd. is preparing for an IPO to raise funds primarily for core pipeline research and development, production facility expansion, and commercialization capabilities [4] Company Overview - Established in 2007, Changfeng Pharmaceutical focuses on the research, production, and commercialization of inhalation technology and inhalation drugs, specifically targeting respiratory diseases [1] Market Opportunity - The global respiratory drug market is substantial, with nearly 2.5 billion people suffering from chronic respiratory diseases. The market is projected to grow from USD 99.9 billion (approximately RMB 729.2 billion) in 2024 to USD 157.2 billion (approximately RMB 1,147.4 billion) by 2033, reflecting a compound annual growth rate (CAGR) of 5.2% [3] Product Pipeline - The company has developed a pipeline of 16 products, with over 60% focused on respiratory diseases, addressing the clinical needs of 250 million respiratory disease patients in China. Key products include: - Recombinant human interferon β1b nebulized solution for viral pneumonia, currently in Phase III clinical trials - Salbutamol inhalation powder for asthma treatment, also in Phase III clinical trials, expected to submit for listing in 2026 [5][6] Technological Advantages - Changfeng Pharmaceutical's core technology is dry powder inhalation (DPI), supported by 32 Chinese patents and 11 international patents. Key advantages include: - Proprietary formulation technology that enhances drug stability by over 200% - Development of an active dry powder inhaler that improves patient compliance, especially among the elderly [7] Commercialization Capability - The company has achieved revenue scale through generic drug sales, with projected revenue of RMB 420 million in 2024, driven by two inhalation products contributing over 80% of revenue. Notable product performances include: - Ambroxol oral solution with a market share of 7.3% - Budesonide suspension with a projected sales growth of 56% year-on-year [8] Industry Landscape - The inhalation formulation market in China is expected to reach RMB 112 billion by 2024, with a CAGR of 18.7% from 2019 to 2024. There is significant potential for domestic companies to replace imported products, as foreign firms currently hold 72% of the market share. Changfeng aims to be the first domestic company to combine generic and innovative drug strategies in the respiratory field [9]

Core Viewpoint - The return of the original brand Mucosolvan (Ambroxol Hydrochloride) to the Chinese market is anticipated in December 2025, following its exit due to registration expiration and increased competition from generic drugs [1][2]. Group 1: Company Background - Mucosolvan was originally developed by Boehringer Ingelheim and launched in Germany in 1978, entering the Chinese market in 1991 [2]. - The product achieved peak sales exceeding 8 billion yuan in China, making it a highly competitive product in the market [2]. - The original manufacturer, Boehringer Ingelheim, ceased the product's registration in China in 2020, leading to its market exit [3]. Group 2: Market Competition - The return of Mucosolvan will face competition from 367 similar drug approvals in China, including significant price competition from generics [6]. - In the 2021 centralized procurement, Boehringer Ingelheim's bid was only a 0.3% price reduction, while competitors like Yunnan Longhai offered a 93.3% reduction [4]. - The market for expectorants is crowded, with other active ingredients available, such as bromhexine and acetylcysteine, which may affect Mucosolvan's market share [6]. Group 3: Future Outlook - The product's return is now under the management of Opella, a company that became independent from Sanofi in May 2025, which retains a 48.2% stake in Opella [4]. - The ability of Mucosolvan to regain consumer trust and willingness to pay a premium in a low-price environment remains uncertain [6]. - The performance of Mucosolvan post-return will be closely monitored, especially regarding its positioning in the OTC market [6].